Critical appraisal of trastuzumab in treatment of advanced stomach cancer

This article was published in the following Dove Press journal:
Cancer Management and Research
3 March 2011
Number of times this article has been viewed

Abstract: Advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. In North America, about 70% of cases are advanced or metastatic when diagnosed, which is higher than the 50% reported in Japan. This difference in presentation is reflected in 5-year overall survival, which is about 20% in North America and 40%–60% in Japan. Despite numerous efforts of randomized studies on advanced gastric cancer, no globally accepted standard regimen has yet been established. Systemic chemotherapy provides palliation and prolongs survival, but the prognosis remains poor. Several monotherapies and combined regimens are currently available and vary around the world. Additionally, several molecular targeting agents are under evaluation in international randomized studies. Human epidermal growth factor receptor-2 (HER-2) is overexpressed or amplified in approximately 22% of patients with gastric cancer. Trastuzumab, a recombinant humanized anti-HER-2 monoclonal antibody, is the first biological therapy that has showed a survival improvement by nearly three months (reduced risk of death by 26%). Therefore, trastuzumab in combination with cisplatin is a reasonable treatment option for patients with advanced gastric cancer who are HER-2 positive. This paper will focus on trastuzumab, its chemical and pharmacological characteristics, and the relevant efficacy, safety, and tolerability studies.

Keywords: gastric cancer, HER-2, trastuzumab

Management issues in stomach cancer
Gastric cancer is a cause of considerable morbidity and mortality the second leading cause of cancer-related death, and the third most common malignancy worldwide. In the US, it was estimated that there would be 21,000 new cases and 10,570 deaths from gastric cancer in 2010. In Japan, there are more than 100,000 new cases diagnosed and 50,000 who die annually. In Western countries, most newly diagnosed cases (73%) will present in the advanced stages when gastric cancer is incurable, having a median survival of less than 1 year. Although 52% of gastric cancer cases in Japan are diagnosed at an early stage, this fact may be related to mass screening.

Fluoropyrimidines, platinums, taxanes, and irinotecan are considered the main active cytotoxic agents for advanced gastric cancer. Palliative chemotherapy for advanced or metastatic gastric cancer offers significant advantages in selected fit patients, including increased survival, symptom control, and quality of life, compared with best supportive care alone. Systematic review showed that the overall survival benefit of chemotherapy over best supportive care was six months (hazards ratio [HR] 0.39, 95% confidence interval [CI]: 0.28–0.52). A three-drug regimen including 5-flourouracil, anthracyclines, and cisplatin has showed the best survival results,
with an HR of 0.83 (95% CI: 0.74–0.93) over single-agent 5-flourouracil-based chemotherapy. ECF (epirubicin + cisplatin + infusional 5-flourouracil) response rates are 40%, with a median survival of 9.4 months and 40% of patients alive at 1 year.10 When oxaliplatin is substituted for cisplatin, and capecitabine for 5-flourouracil (EOX), response rates are 48%, median survival 11.2 months, and 1-year survival 48%. Interestingly, thromboembolic events were significantly higher in cisplatin groups than in oxaliplatin groups (15.1 versus 7.6%, \( P < 0.001 \)).11

Docetaxel combined with cisplatin ± 5-flourouracil (DCF) has better response rates, longer progression-free survival, and a small survival advantage compared with cisplatin + 5-flourouracil (9.2 versus 8.6 months, \( P = 0.02 \)).12,13 However, in patients older than 65 years, increased toxicity of neutropenic infection and diarrhea has been seen. Irinotecan is also an active drug for advanced gastric cancer, although no improvement in survival has been demonstrated in randomized trials.14–16 It may be a more appropriate choice than cisplatin + 5-flourouracil, given its better tolerance. DCF and 5-flourouracil plus irinotecan regimens have not been directly compared against ECF.

Tegafur, a 5-flourouracil prodrug, is mainly used in Japan. Phase III trials have demonstrated that tegafur is not inferior to 5-flourouracil in overall survival, and it is associated with higher response rates, longer progression-free survival, longer time to treatment failure, and longer nonhospitalized survival.17 Tegafur combined with irinotecan was not significantly better compared with tegafur alone.18 However, when it was combined with cisplatin, significantly longer survival was seen than for tegafur alone, with acceptable toxicities. This regimen is standard therapy for metastatic gastric cancer in Japan.19

Although a large number of chemotherapeutic regimens have been proven in Phase III studies, there is no internationally accepted standard of care. Monotherapy with 5-flourouracil or doublets with 5-flourouracil and cisplatin, irinotecan, or an anthracycline, are reasonable options for patients who are not candidates for ECF. DCF may be recommended in very fit selected patients. Additionally, a preliminary updated meta-analysis suggested that chemotherapy combinations including irinotecan, oxaliplatin, docetaxel, or oral 5-flourouracil prodrugs, are alternative treatment options to cisplatin/5-flourouracil or cisplatin/5-flourouracil/ anthracycline-combinations, but do not provide significant advantages in overall survival.20 Median time to progression after first-line chemotherapy for metastatic gastric cancer is typically 3–5 months. No second-line regimen has been established, and historically few patients are considered for second-line treatment (20%). However, recent data from a randomized trial showed that 39%–48% of patients in a sequence of chemotherapy including ECF followed by FOLFIRI (leucovorin + 5-flourouracil + irinotecan) and the reverse sequence, received a second-line chemotherapy.21 So far, there are only preliminary data from a Phase III study in 40 patients that compared irinotecan monotherapy versus best supportive care in second line, demonstrating that irinotecan significantly prolongs overall survival (by 50.5 days) and improves tumor-related symptoms.22 Some Phase II studies have been published; taxanes and irinotecan are the most commonly used drugs in this setting, as monotherapy or in combined chemotherapy. Responses vary from 0% to 50%, and time to progression and overall survival has been reported to be 3–6 and 6–9 months, respectively. Predictors of response have been described, including performance status, locally advanced rather than metastatic disease, and previous response to first-line therapy.23–26

Molecular targeting agents, alone or in combination with chemotherapy, are being tested in the second-line setting.27–29 Despite the benefits of palliative chemotherapy, and the diversity of chemotherapy regimens, the prognosis of advanced gastric cancer remains poor, with a median overall survival of 7–10 months. An increased understanding of molecular pathways has provided novel targets to treat cancer patients. Several molecularly targeted agents are under evaluation in patients with advanced gastric cancer.30,31

Bevacizumab combined with chemotherapy (cisplatin and irinotecan; oxaliplatin and docetaxel or 5-flourouracil; DCF) has shown promising results in Phase II studies including treated and untreated patients (response rates 63%–71%). However, the main concern arising from these trials is toxicity.32–35

A recent update of a Phase III trial including 774 patients with advanced gastric cancer who received combined chemotherapy (capecitabine/5-flourouracil + cisplatin) with bevacizumab or placebo did not show significant differences in overall survival (12.1 versus 10.1 months, respectively), although there were significant improvements in progression-free survival and overall response rate, with an acceptable safety profile favoring the bevacizumab arm.

Sunitinib has demonstrated disease control rates of 40%.36 Additionally, preliminary results showed encouraging response rates when sunitinib is combined with chemotherapy, such as tegafur, capecitabine + cisplatin, or capecitabine + oxaliplatin.37–39 Sorafenib in combination with docetaxel
cisplatin showed an encouraging efficacy profile, with tolerable toxicity (40% partial response rate).\textsuperscript{40}

Cetuximab showed poor response rates (5%) in pretreated patients.\textsuperscript{41} However, in combination with 5-fluorouracil and oxaliplatin or irinotecan, a relative risk of 52%–65% was seen in previously untreated patients.\textsuperscript{42–44} Cetuximab in combination with docetaxel and cisplatin has a response rate of 42%.\textsuperscript{45}

Addition of matuzumab to EOX did not improve tumor response or survival in patients with advanced gastric cancer.\textsuperscript{46} Most clinical trials using epidermal growth factor receptor tyrosine kinase inhibitors in gastric cancer have shown minimal efficacy. Erlotinib had a response rate of 10% in previously untreated patients,\textsuperscript{47} and gefitinib had an 18% stable disease rate in previously treated patients.\textsuperscript{48} Preliminary results with lapatinib showed a 7% and 20% partial response and stable disease rate, respectively, in untreated patients.\textsuperscript{49} A preliminary report of a Phase II study showed that in combination with capecitabine, a partial response and stable disease were seen in 24% and 34%, respectively.\textsuperscript{50} The EOX regimen with or without panitumumab (REAL-3 study) is ongoing,\textsuperscript{51} with Phase I trials of the combination showing a response rate of 65%.\textsuperscript{52}

**Pharmacology and pharmacokinetics**

Human epidermal growth factor receptor (HER)-2/neu (c-erbB-2) is a transmembrane tyrosine kinase receptor, and a member of the HER family (HER-1, 2, 3, and 4). HER-2 functions as an oncogene. Gene amplification induces protein overexpression in cell membranes, and regulates signal transduction in cellular processes, including proliferation, differentiation, and cell survival.\textsuperscript{53,54} Aberrant HER-2 expression or function has been implicated in breast and gastric carcinogenesis, and is evident in other cancer types, including ovarian, salivary gland, and prostate and lung cancers.\textsuperscript{53,55}

Trastuzumab is a recombinant humanized anti-HER-2 MAb (rhuMAb HER-2), directed against the HER-2 extracellular domain.\textsuperscript{55} Several trastuzumab antitumor activities have been described\textsuperscript{53,56} (see Figure 1):

- Blocking of HER-2 receptor cleavage and inhibiting dimerization
- Increasing receptor destruction by endocytosis
- Inhibiting intracellular pathway signaling such as phosphoinositide 3-kinase signaling; may indirectly modulate proangiogenic and antiangiogenic factors, such as vascular endothelial growth factor production
- Inducing G1 phase arrest by inducing the cyclin-dependent kinase inhibitor, p27 Kip1

- Cytostatic and cytotoxic activity due to immune system recruitment by antibody-dependent cell-mediated cytotoxicity.

The pharmacokinetics and pharmacodynamics of trastuzumab are not completely understood. Most studies have been done in breast cancer patients. Trastuzumab has a low systemic clearance (5.15 ± 2.45 mL/kg/day) and a low volume of distribution (44 mL/kg). The half-life may vary from 1.1 to 28 days with infusions of 10 mg and 500 mg, respectively. Half-lives of 2.7, 3.1, 8.8, and 10.4 days were found after single doses of 1, 2, 4, and 8 mg/kg, respectively, suggesting that, after trastuzumab receptors become saturated, total body clearance becomes linear. Doses of 4 mg/kg and 8 mg/kg are enough to achieve and maintain the serum minimum concentrations (10 µg/mL) needed for anti-proliferative effects and antibody-dependent cell-mediated cytotoxicity.\textsuperscript{57} Using a loading dose of 4 mg/kg followed by 2 mg/kg/week, trastuzumab achieves and maintains serum minimum concentrations greater than 20 µg/mL.\textsuperscript{58}

No drug interactions have been reported. No monoclonal antibody has been found to interact with major molecular pharmacokinetic determinants, such as enzymes, drug transporters, or orphan nuclear receptors. Using an initial dose of 4 mg/kg followed by 2 mg/kg/week, in combination with chemotherapy, the mean peak serum trastuzumab concentration is similar to that in patients receiving trastuzumab alone (101.0 µg/mL at week 8 and 53.4 µg/mL of mean minimum concentration).\textsuperscript{58,59} Elimination pathways are not yet defined, and the clinical relevance of trastuzumab kinetic variability is unknown. However, trastuzumab elimination seems to depend on high serum levels of circulating HER-2 extracellular domains, which can be cleaved from the surfaces of cancer cells by matrix metalloproteinase and released into the serum. Patients with high HER-2 extracellular domain levels tend to have a shorter trastuzumab half-life and lower minimum concentrations. Patients with four or more metastatic sites have faster clearance, independent of HER-2 extracellular domain levels. This is influenced little by trastuzumab exposure, and trastuzumab steady-state plasma levels are normally much higher than those of HER-2 extracellular domain levels.\textsuperscript{58,59}

**Efficacy studies in gastric cancer**

Overexpression and amplification of HER-2/ErbB2 in gastric cancer vary widely, from 6% to 45%.\textsuperscript{59–64} The largest report screened 3883 patients with advanced gastric cancer from 24 countries, and found 22.1% HER-2-positivity rates in 3807 evaluated patients. Immunohistochemical and fluorescence in situ hybridization concordance was 87.3%. HER-2 positivity
was higher in gastroesophageal junction cancers than in gastric cancers (33.2% versus 20.9%, \( P < 0.001 \)), and higher in intestinal cancers than in diffuse/mixed cancers (32.2% versus 6.1%/20.4%, \( P < 0.001 \)). No differences were seen between European and Asian countries.\(^6\)\(^5\)

Early studies in HER-2-positive gastric cancer cell lines, showed the growth inhibitory effects of trastuzumab. Additionally, when combined with doxorubicin, cisplatin, or paclitaxel, it demonstrated increased cytotoxicity, suggesting that a regimen based on these combinations could be considered for gastric cancer\(^6\)\(^6\) (see Table 1).

**Table 1** Trastuzumab in gastric cancer: Preclinical and clinical trials

<table>
<thead>
<tr>
<th>Authors</th>
<th>Type of study</th>
<th>n</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gong et al(^6)(^6)</td>
<td>Preclinical</td>
<td>Cell lines</td>
<td>Antitumor activity</td>
</tr>
<tr>
<td>Cortés-Funes et al(^7)</td>
<td>Phase II</td>
<td>T + D</td>
<td>21</td>
</tr>
<tr>
<td>Egamberdiev et al(^8)</td>
<td>Phase II</td>
<td>T + C</td>
<td>16</td>
</tr>
<tr>
<td>Van Cutsem E et al(^9)</td>
<td>Phase III</td>
<td>T + Cap/5-FU</td>
<td>597</td>
</tr>
</tbody>
</table>

**Abbreviations:** T, trastuzumab; C, cisplatin; D, doxorubicin; Cap, capecitabine; CT, chemotherapy; PR, partial response; SD, stable disease; OS, overall survival; OR, objective response; 5-FU, 5-fluorouracil.

Cortés-Funes et al\(^8\)\(^7\) have reported the preliminary results of a small Phase II study of 21 patients with advanced gastric cancer and HER-2 overexpression/amplification who received trastuzumab 8 mg/kg as a loading dose in the first cycle, followed by 6 mg/kg every 21 days, and cisplatin 75 mg/m\(^2\) every 21 days. These patients showed response rates of 35% and stable disease of 17%. The therapy was well tolerated, with no Grade 4 toxicity reported.

Similarly, Egamberdiev et al,\(^8\)\(^8\) in a small preliminary study of 16 patients with HER-2-positive advanced gastric cancer treated with trastuzumab 6 mg/kg and chemotherapy (cisplatin, 5-fluorouracil, and leucovorin) every three weeks, found an objective response rate of 55% and a median overall survival of eight months.

The ToGA study is the first randomized, controlled Phase III trial to evaluate the efficacy and safety of trastuzumab in advanced HER-2-positive gastric cancer. Five hundred and ninety-four patients received either trastuzumab in combination with 5-fluorouracil/capecitabine and cisplatin or chemotherapy alone. The chemotherapy group (control arm) received capecitabine 1000 mg/m\(^2\) twice a day for 14 days or continuous infusion of 5-fluorouracil 800 mg/m\(^2\)/day on days 1–5 of each cycle, plus cisplatin 80 mg/m\(^2\) on day 1 every three weeks. The experimental arm received the same chemotherapy plus trastuzumab 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every three weeks. The final report at 18.6 months of
median follow-up for the experimental arm and 17.1 months for the control arm showed better median survival with the combination (13.8 versus 11.1 months, \( P = 0.0046; \) HR 0.74, 95% CI: 0.60–0.91) with a 26% reduction in risk of death. Progression-free survival was 6.7 versus 5.5 months \( (P = 0.0002) \), and tumor response (including complete and partial response) was 47% versus 35% \( (P = 0.0017) \) with the addition of trastuzumab versus chemotherapy alone. Toxicity, including cardiac adverse events, was similar in both groups. More than 40% of patients in both groups received second-line treatment. Subgroup analysis for survival favored trastuzumab throughout (site of tumor, performance status, fluoropyrimidine used, histology, age, region, prior gastrectomy, and number of metastatic sites). Patients with high immunohistochemical positivity for HER-2 had a trend for better survival in the preplanned analysis (16 months) with trastuzumab compared with chemotherapy alone (11.8 months). This finding suggests that levels of HER2 protein expression predict response to trastuzumab, similar to what has been described in metastatic breast cancer. Therefore, patients with advanced gastric cancer and these tumor characteristics should be offered trastuzumab plus chemotherapy as a treatment option.

**Safety and tolerability**

The most common adverse events with trastuzumab are infusion-related reactions (fever, rigors, chills, nausea, dyspnea, and hypotension), present in about 40% of patients with the first dose and in 5% with subsequent doses. Myelosuppression, nausea, and vomiting are rare, and alopecia has not been reported with monotherapy. However, quantifying the contribution of trastuzumab to these side effects is difficult when it is given in combination with chemotherapy. In the ToGA trial, serious adverse events were reported in 32% of patients treated with trastuzumab plus chemotherapy and 28% in the chemotherapy alone group. Treatment-related mortality was 3% and 1% in the experimental and control arm, respectively.

Special attention has focused on the cardiotoxicity of trastuzumab. Sporadic cases of congestive heart failure were reported in the early trials. However, an association between impairment of left ventricular ejection fraction and trastuzumab was more evident when given in combination with chemotherapy. The pivotal study in breast cancer showed cardiac toxicity in 27% of patients when trastuzumab was combined with anthracyclines, in 13% when it was combined with paclitaxel, and in 5% with trastuzumab alone. The ToGA trial reported cardiac event rates of 6%. Postmarketing surveillance for trastuzumab has reported that 62 of 25,000 (0.002%) patients have had serious adverse events (hypersensitivity reactions, infusion-related reactions, and pulmonary events). Adult respiratory distress syndrome, anaphylaxis, and death within 24 hours of a trastuzumab infusion were reported. Fatal events occurred mostly in patients with pre-existing pulmonary dysfunction, so these patients should be treated with caution, and trastuzumab should be discontinued if severe infusion-related reactions occur. A Phase IV trial is currently underway to evaluate the efficacy and safety of trastuzumab in patients with advanced HER-2 gastric cancer.

**Patient-focused perspectives**

Ideally, any gain in survival should also be accompanied by an improvement in or at least stable quality of life. Assessment of quality of life with trastuzumab therapy has been studied in breast cancer patients, with favorable results. There are no available data in patients with gastric cancer as yet. Osoba et al found that patients treated with trastuzumab plus chemotherapy had significantly better improvement in quality of life (51%) than patients treated with chemotherapy alone (36%).

More recently, Rugo et al demonstrated that patients treated with chemotherapy and trastuzumab versus chemotherapy alone had more improvement in quality of life (51% versus 36%, respectively). Improved physical, role functioning, and fatigue were also seen in the combined therapy arm.

**Discussion**

Gastric cancer is an aggressive disease with a high mortality rate, and despite recent progress in diagnosis, surgical techniques, chemotherapy, and radiotherapy, the prognosis remains poor. Advanced or metastatic gastric cancer constitutes the majority of patients in Western clinical practice. Chemotherapy has been considered the standard, with the significant advantages of increased survival, symptom control, and quality of life, compared with best supportive care alone. Trastuzumab is the first monoclonal antibody that has been shown to prolong life in patients with a malignant epithelial condition. In HER-2 breast cancer patients, its impact has been considerable. For advanced gastric cancer patients, trastuzumab is the first biological therapy that has showed a survival benefit. The ToGA trial included patients selected for treatment according to molecular profile. Encouragingly, trastuzumab in combination with chemotherapy showed a median survival of 13.8 months. Trastuzumab is a reasonable treatment option for patients with HER-2-positive advanced gastric cancer, although only approximately 20% of patients would be potential candidates. Some patients with...
HER-2-positive disease demonstrated primary or secondary resistance. Mechanisms of resistance and potential strategies to overcome these have been extensively researched in breast cancer, including loss of phosphatase and tensin homolog protein, activating mutations in the gene encoding phosphatidylinositol kinase-3, and increased signaling through other receptors (epithelial growth factor receptor and insulin-like growth factor-I receptor). Lapatinib, the dual HER-2/epithelial growth factor receptor inhibitor, prolongs time to progression in patients with trastuzumab-resistant HER-2-positive breast cancer, and warrants evaluation in trastuzumab-resistant HER-2-positive gastric cancer.

Two Phase II trials, one combining chemotherapy (capecitabine and oxaliplatin) and targeted therapy (bevacizumab and trastuzumab), and the other with trastuzumab in combination with tegafur and cisplatin in advanced gastric cancer are planned. Additionally, two Phase II studies evaluating lapatinib in combination with capecitabine and weekly paclitaxel in first-line and second-line settings, respectively, in advanced gastric cancer are open to recruitment.

Further research is needed to evaluate the efficacy of trastuzumab as monotherapy, maintenance treatment, and second-line therapy for advanced gastric cancer. Moreover, trastuzumab should be integrated into curative treatment trials for patients with gastric cancer, such as perioperative or postoperative therapy.

With a better understanding of gastric cancer epidemiology and an ability to categorize it into distinct clinical and pathologic entities, improvement in gastric cancer therapy is expected. Moreover, by improving our knowledge of gastric cancer biology and signaling pathways, integration of targeted therapies has become possible and promising. Better selection of patients for a particular therapy will significantly improve treatment paradigms for this deadly disease, with the possibility of also improving patient survival. Several clinical trials with targeted therapies, including bevacizumab, cetuximab, panitumumab, and lapatinib in combination with conventional chemotherapy regimens, are currently ongoing, which may help to increase our armamentarium against gastric cancer.

Disclosure
The authors report no conflicts of interest in this work.

References


